Compare EVLV & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVLV | CGEM |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 994.7M | 1.1B |
| IPO Year | 2020 | 2020 |
| Metric | EVLV | CGEM |
|---|---|---|
| Price | $6.05 | $19.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $9.13 | ★ $30.13 |
| AVG Volume (30 Days) | ★ 1.6M | 511.7K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $145,905,000.00 | N/A |
| Revenue This Year | $21.67 | N/A |
| Revenue Next Year | $19.50 | $5.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.48 | N/A |
| 52 Week Low | $4.61 | $5.68 |
| 52 Week High | $8.90 | $19.43 |
| Indicator | EVLV | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 63.78 |
| Support Level | $5.23 | $11.87 |
| Resistance Level | $6.82 | N/A |
| Average True Range (ATR) | 0.21 | 0.95 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 87.88 | 97.35 |
Evolv Technologies Holdings Inc is a security technology company pioneering Artificial Intelligence (AI)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. It serves customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. The company operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.